July 13, 2022 12:47 PM EDTUpdated 01:27 PM
Pharma
Law

Al­ny­lam sues Mod­er­na and Pfiz­er again over Covid-19 vac­cine patent in­fringe­ment

Aayushi Pratap

News Reporter

The patent bat­tle over Covid-19 vac­cine de­liv­ery tech­nol­o­gy in­ten­si­fied yes­ter­day af­ter Al­ny­lam Phar­ma­ceu­ti­cals yet again ac­cused Mod­er­na and Pfiz­er of vi­o­lat­ing patents.

In two sep­a­rate …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

A service from the Financial Times